Health Technology · Pharmaceuticals: Major · NSE: IPCALAB · data 2026-10-09

IPCA Laboratories Limited

Health check: Strong (8.4/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹1,915.4

Market cap

₹48,932 cr

P/E

37.1

P/B

—

ROE

15.2%

ROCE

16.3%

Debt / equity

0.1

Dividend yield

0.31%

1-year return

40.6%

52-week high

₹2,038

52-week low

₹1,251.6

Operating margin

17.4%

Growth

Revenue (last 12 months)	₹10,126 cr
Net profit (last 12 months)	₹1,310 cr
Sales growth, 3 years (yearly)	15.6%
Profit growth, 3 years (yearly)	34.3%

Similar companies

Biocon Limited (BIOCON) · Abbott India Limited (ABBOTINDIA) · Gland Pharma Ltd. (GLAND) · Ajanta Pharma Limited (AJANTPHARM) · GlaxoSmithKline Pharmaceuticals Limited (GLAXO)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open IPCALAB in NSE Scanner →